Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Maxigen Biotech's share price for the quarter that ended in Dec. 2024 was NT$48.95. Maxigen Biotech's Shares Outstanding (EOP) for the quarter that ended in Dec. 2024 was 89.2 Mil. Therefore, Maxigen Biotech's market cap for the quarter that ended in Dec. 2024 was NT$4,364.5 Mil.
Maxigen Biotech's quarterly market cap
declined
from Jun. 2024 (NT$4,115.0 Mil) to Sep. 2024 (NT$3,803.3 Mil) but then
increased
from Sep. 2024 (NT$3,803.3 Mil) to Dec. 2024 (NT$4,364.5 Mil).
Maxigen Biotech's annual market cap
increased
from Dec. 2022 (NT$4,035.9 Mil) to Dec. 2023 (NT$4,304.4 Mil) and
increased
from Dec. 2023 (NT$4,304.4 Mil) to Dec. 2024 (NT$4,364.5 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Maxigen Biotech's Enterprise Value for Today is NT$3,425.3 Mil.
Maxigen Biotech Market Cap Historical Data
The historical data trend for Maxigen Biotech's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Maxigen Biotech's Market Cap
For the Medical Instruments & Supplies subindustry, Maxigen Biotech's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Maxigen Biotech's Market Cap Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Maxigen Biotech's Market Cap distribution charts can be found below:
* The bar in red indicates where Maxigen Biotech's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Maxigen Biotech's Market Cap for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Maxigen Biotech (TPE:1783) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Maxigen Biotech Market Cap Related Terms
Thank you for viewing the detailed overview of Maxigen Biotech's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Maxigen Biotech Inc specializes in the developing, manufacturing, and marketing of biomedical and cosmeceutical skincare products. It provides medical devices for orthopedic, ophthalmic, dental, and surgical applications. Skincare product categories include mask series, facial cleansing series, and body care series. The biomedical products segment is mainly engaged in the manufacturing and sales of collagen and bone materials, which forms the majority chunk of the revenue of the group. The consumer products segment is engaged in the manufacturing and sales of beauty care products. It generates the majority of the revenue from the Biomedical products segment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TPE:1783 has been successfully added to your 